Overexpression of platelet-derived growth factor-D as a poor prognosticator in endometrial cancer

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 8, 2014, Pages 3741-3745

  Ding, Jie ^a   Li, Xiao Mao ^a   Liu, Sui Ling ^a   Zhang, Yu ^a   Li, Tian ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Clinicopathologic features; Endometrial cancer; PDGF D; Prognosis

Indexed keywords

LYMPHOKINE; PDGFD PROTEIN, HUMAN; PLATELET DERIVED GROWTH FACTOR; VASCULOTROPIN A;

AGED; CARCINOMA; CASE CONTROL STUDY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; UPREGULATION; WESTERN BLOTTING;

AGED; BLOTTING, WESTERN; CARCINOMA; CARCINOMA, ENDOMETRIOID; CASE-CONTROL STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOKINES; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PLATELET-DERIVED GROWTH FACTOR; PROGNOSIS; RETROSPECTIVE STUDIES; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84902007643     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.8.3741     Document Type: Article

References (26)

1. Aas T, Borresen AL, Geisler S, et al (1996). Specific P53 mutations are associated with denovo resistance to doxorubicin in breast cancer patients. Nat Med, 2, 811-4.
2. Creasman WT, Morrow CP, Bundy BN, et al (1987). Surgical pathologic spread patterns of endometrial cancer. Cancer, 60, 2035-41.
3. Deuel TF (1987). Polypeptide growth factors: roles in normal and abnormal cell growth. Annu Rev Cell Biol, 3, 443-92.
4. Engelsen IB, Stefansson IM, Akslen LA, et al (2008). GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival. Am J Obstet Gynecol, 199, 541-7.
5. Hwang RF, Yokoi K, Bucana CD, et al (2003). Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res, 9, 6534-44.
6. Jemal A, Siegel R, Xu J, et al (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300.
7. Kong D, Banerjee S, Huang W, et al (2008). Mammalian target of rapamycin repression by3,3'-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D over-expressing PC3 cells. Cancer Res, 68, 1927-34.
8. LaRochelle WJ, Jeffers M, Corvalan JR, et al (2002). Platelet derived growth factor D: tumorigenicity in mice and dysregulated expression in human cancer. Cancer Res, 62, 2468-73.
9. Lokker NA, Sullivan CM, Hollenbach SJ, et al (2002). Platelet-derived growth factor autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res, 62, 3729-35.
10. Mannelqvist M, Stefansson IM, Bredholt G, et al (2010). Gene expression patterns related to vascular invasion and aggressive features in endometrial cancer. Am J Pathol, 178, 861-71.
11. Mannelqvist M, Stefansson IM, Salvesen HB, et al (2009). Importance of tumour cell invasion in blood and lymphatic vasculature among patients with endometrial carcinoma. Histopathology, 54, 174-83.
12. Rosenkranz S, Kazlauskas A (1999). Evidence for distinct signaling properties and biological responses induced by the PDGF receptor alpha and beta subtypes. Growth Factors, 16, 201-16.
13. Stefansson IM, Salvesen HB, Akslen LA (2006). Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Res, 66, 3303-9.
14. Stefansson IM, Salvesen HB, Immervoll H, et al (2004). Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type. Histopathology, 44, 472-9.
15. Ustach CV, Kim HR (2005). Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells. Mol Cell Biol, 25, 6279-88.
16. Ustach CV, Taube ME, Hurst NJ, et al (2004). A potential oncogenic activity of platelet-derived growth factor d in prostate cancer progression. Cancer Res, 64, 1722-9.
17. Wan J, Li X (2012). PELP1/MNAR suppression inhibits proliferation and metastasis of endometrial carcinoma cells. Oncology Reports, 12, 2035-42.
18. Wang HL, Ren YF, Yang J, et al (2013).Total laparoscopic hysterectomy versus total abdominal hysterectomy for endometrial cancer: a meta-analysis. Asian Pac J Cancer Prev, 14, 2515-9.
19. Wang XW, Zhong TY, Xiong YH, et al (2012). Lack of association between the ,CYP1A1 Ile462Val polymorphism and endometrial cancer risk: a meta-analysis. Asian Pac J Cancer Prev, 13, 3717-21.
20. Wang ZW, Ahmad A, Li YW, et al (2010). Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim Biophys Acta, 1806, 122-30.
21. Wang ZW, Kong DJ, Banerjee S, et al (2007). Down-regulation of platelet derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and Nuclear Factor-κB Signaling. Cancer Res, 67, 11377-85.
22. Wang ZW, Kong DJ, Li YW, et al (2009). PDGF-D signaling: a novel target in cancer therapy. Curr Drug Targets, 10, 38-41.
23. Xiao L, Yang YB, Li XM, et al (2010). Differential sensitivity of human endometrial carcinoma cells with different PTEN expression to mitogen-activated protein kinase signaling inhibits and implications for therapy. J Cancer Res Clin Oncol, 136, 1089-99.
24. Xu C, Li X, Li T, et al (2011). Combination effects of paclitaxel with signaling inhibitors in endometrial cancer cells. Asian Pac J Cancer Prev, 12, 2951-7.
25. Xu L, Tong R, Cochran DM, et al (2005). Blocking platelet derived growth factor-D/platelet-derived growth factor receptor signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res, 65, 5711-9.
26. Yu J, Ustach C, Kim HR (2003). Platelet-derived growth factor signaling and human cancer. J Biochem Mol Biol, 36, 49-59.